Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) PT at $47.20

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOKGet Rating) have been assigned a consensus rating of “Buy” from the eight analysts that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $47.20.

A number of equities analysts recently weighed in on STOK shares. Bank of America reduced their target price on shares of Stoke Therapeutics from $43.00 to $40.00 and set a “buy” rating for the company in a research note on Wednesday, March 16th. Zacks Investment Research downgraded shares of Stoke Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, March 16th. Jefferies Financial Group started coverage on shares of Stoke Therapeutics in a research note on Monday, January 31st. They set a “buy” rating and a $50.00 price objective for the company. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research note on Friday, April 1st.

Shares of NASDAQ STOK opened at $20.34 on Tuesday. Stoke Therapeutics has a 1-year low of $16.62 and a 1-year high of $41.60. The company has a fifty day moving average price of $21.10 and a 200 day moving average price of $22.13.

Stoke Therapeutics (NASDAQ:STOKGet Rating) last announced its earnings results on Thursday, March 10th. The company reported ($0.66) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.04). Sell-side analysts expect that Stoke Therapeutics will post -1.66 earnings per share for the current year.

A number of large investors have recently modified their holdings of the stock. Barclays PLC lifted its stake in Stoke Therapeutics by 152.7% in the 4th quarter. Barclays PLC now owns 23,169 shares of the company’s stock valued at $556,000 after purchasing an additional 14,000 shares during the last quarter. BlackRock Inc. lifted its stake in Stoke Therapeutics by 4.9% in the 4th quarter. BlackRock Inc. now owns 1,482,265 shares of the company’s stock valued at $35,559,000 after purchasing an additional 69,147 shares during the last quarter. Susquehanna International Group LLP raised its holdings in Stoke Therapeutics by 440.4% in the 4th quarter. Susquehanna International Group LLP now owns 28,090 shares of the company’s stock valued at $674,000 after acquiring an additional 36,342 shares during the period. Marshall Wace LLP bought a new position in Stoke Therapeutics in the 4th quarter valued at about $1,017,000. Finally, Millennium Management LLC raised its holdings in Stoke Therapeutics by 172.9% in the 4th quarter. Millennium Management LLC now owns 149,625 shares of the company’s stock valued at $3,590,000 after acquiring an additional 94,800 shares during the period. Institutional investors and hedge funds own 96.93% of the company’s stock.

Stoke Therapeutics Company Profile (Get Rating)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression.

See Also

Analyst Recommendations for Stoke Therapeutics (NASDAQ:STOK)

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.